Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R).
Several tetrahydroimidazopyrimidines were prepared using silver assisted cyclization as the key step. The binding affinities of compounds thus prepared were evaluated in vitro toward hCRF(1)R. Initial lead compound 16 (K(i)=32 nM) demonstrated modest putative anxiolytic effects in the mouse canopy test. Further optimization using parallel synthesis provided compounds with K(i)'s <50 nM.
Vrudhula
Vivekananda M
VM
Bristol-Myers Squibb Research & Development, Wallingford, CT 06492, USA. vivekananda.vrudhula@bms.com
Dasgupta
Bireshwar
B
Pin
Sokhom S
SS
Burris
Kevin D
KD
Balanda
Lynn A
LA
Fung
Lawrence K
LK
Fiedler
Tracey
T
Browman
Kaitlin E
KE
Taber
Matthew T
MT
Zhang
Jie
J
Macor
John E
JE
Dubowchik
Gene M
GM
D000818:Animals; D003500:Cyclization; D015195:Drug Design; D051379:Mice; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D000099052:CRF Receptor, Type 1
D011743:Pyrimidines; D018019:Receptors, Corticotropin-Releasing Hormone; D000099052:CRF Receptor, Type 1